Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,084 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,469 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06839053 | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | recruiting | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07545603 | Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma | recruiting | Phase 2 | 65 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01816971 | Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 76 | University of ChicagoOTHER | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03623373 | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 13 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05392946 | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | active not recruiting | Phase 1 / Phase 2 | 49 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma(LINKER-MM1) | recruiting | Phase 1 / Phase 2 | 387 | Regeneron PharmaceuticalsINDUSTRY | 7 | Apr 20, 2026 | clinicaltrials |
| NCT04166565 | Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease(EMN19) | active not recruiting | Phase 2 | 41 | Stichting European Myeloma NetworkNETWORK | 3 | Apr 20, 2026 | clinicaltrials |
| NCT04561492 | Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma(PentiMyelo) | active not recruiting | Phase 2 | 45 | Nantes University HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04939272 | Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 8 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05909059 | CAR T-cell Therapy in Patients With Renal Dysfunction | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03341520 | Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma(GAZAI) | completed | Phase 2 | 89 | Heidelberg UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07162181 | Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers | active not recruiting | Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | recruiting | Phase 1 / Phase 2 | 152 | Curis, Inc.INDUSTRY | 7 | Apr 16, 2026 | clinicaltrials |
| NCT04189757 | Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | active not recruiting | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05498220 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06378190 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology(TranspoCART19) | recruiting | Phase 1 / Phase 2 | 27 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01424982 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02420860 | Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02719613 | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | completed | Phase 2 | 67 | Bristol-Myers SquibbINDUSTRY | 13 | Apr 15, 2026 | clinicaltrials |
| NCT02960555 | Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) | active not recruiting | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03763162 | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03856216 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05336383 | Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | recruiting | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 4 | Apr 15, 2026 | clinicaltrials |
| NCT07523737 | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02514083 | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | active not recruiting | Phase 2 | 29 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01589302 | PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia | active not recruiting | Phase 2 | 154 | Kami Maddocks, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03500445 | Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | active not recruiting | Phase 2 | 75 | University of ChicagoOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04450173 | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | active not recruiting | Phase 2 | 40 | University of California, DavisOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05955508 | A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | active not recruiting | Phase 2 | 40 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04433156 | VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma | completed | Phase 2 | 26 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05183854 | Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial | recruiting | Phase 2 | 61 | University of UtahOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07319676 | Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 30 | National University Hospital, SingaporeOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT01054196 | Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study | active not recruiting | Phase 1 / Phase 2 | 52 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT01241734 | Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL(RICER) | completed | Phase 1 / Phase 2 | 18 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT01453101 | Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma(Flu-Mel-Vel) | completed | Phase 2 | 54 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02405364 | Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction(IFM-CRd) | completed | Phase 2 | 46 | University Hospital, ToulouseOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03697512 | MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas(MALIBU) | active not recruiting | Phase 2 | 175 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 5 | Apr 8, 2026 | clinicaltrials |
| NCT04404660 | A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | active not recruiting | Phase 1 / Phase 2 | 153 | Autolus LimitedINDUSTRY | 3 | Apr 8, 2026 | clinicaltrials |
| NCT01679119 | Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy(INCA) | completed | Phase 2 | 129 | University College, LondonOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02302495 | Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma(IFM2012-03) | completed | Phase 2 | 32 | University Hospital, LilleOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02626481 | Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma(IFM2014-04) | completed | Phase 2 | 64 | University Hospital, LilleOTHER | 2 | Apr 7, 2026 | clinicaltrials |
| NCT04925193 | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 2 | 18 | University of Colorado, DenverOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT01067287 | Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation | completed | Phase 2 | 35 | Beth Israel Deaconess Medical CenterOTHER | 2 | Apr 6, 2026 | clinicaltrials |
| NCT02518555 | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 42 | Jennifer WoyachOTHER | 1 | Apr 6, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 22, 2026source: clinicaltrials